Prostate cancer incidence and mortality are increasing, with over 313,000 diagnoses and 35,000 deaths projected for 2025. Screening practices, influenced by the US Preventive Services Task Force, have ...

"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares the initial and ...

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD. In this video, Timothy D. Lyon, MD, discusses the Urology Practice ...

Wilms tumor growth patterns differ based on the specific predisposition gene variant and its developmental timing. Around 30% of children with Wilms tumor have a mutation in a predisposition gene, ...

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

"As we all know, Medicare rules do not always follow CPT directives. The same is true in this case," write Jonathan Rubenstein, MD, and Mark Painter. To help answer this question, we should first ...

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

This video segment covers patient selection criteria for different versions of abiraterone, strategies for assessing treatment efficacy and safety, engaging caregivers to monitor compliance and side ...

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...

MPS2 test detects 94% of GG2 or higher prostate cancers using non-DRE urine samples, outperforming PSA and PCPTrc in accuracy. MPS2 models could reduce unnecessary biopsies by 36% to 42%, compared to ...

Signati's Separo system achieved FDA de novo market clearance application after demonstrating safety and effectiveness in GLP data and an IDE study. The Separo system enables a transdermal vasectomy, ...